E-cadherin and caveolin-1 alterations in the heart of rats having undergone chlorpromazine-induced toxicity

Molecular Medicine Reports

Volumn 5, Issue 3, 2012, Pages 705-709

  Huang, Quan Yong ^a   Li, Xue Fang ^a   Liu, Shui Ping ^b  

^a DALI UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Caveolin 1; Chlorpromazine induced toxicity; E cadherin

Indexed keywords

CAVEOLIN 1; CHLORPROMAZINE; DIAMINOBENZIDINE; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; EXPERIMENTAL STUDY; EXTRACELLULAR MATRIX; HEART FUNCTION; HISTOPATHOLOGY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; NONHUMAN; OPTICAL DENSITY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; ROOM TEMPERATURE;

ANIMALS; ANTIEMETICS; CADHERINS; CAVEOLIN 1; CHLORPROMAZINE; GENE EXPRESSION REGULATION; HEART; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIUM; RATS; RATS, WISTAR;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84863078089     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.729     Document Type: Article

References (55)

1. Lopez-Munoz F, Alamo C, Cuenca E, Shen WW, Clervoy P and Rubio G: History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 17: 113-135, 2005. (Pubitemid 41176798)
2. Liu X and De Haan S: Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev 2: CD007778, 2009.
3. Almerie MQ, Alkhateeb H, Essali A, Matar HE and Rezk E: Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database Syst Rev 1: CD006329, 2007.
4. Ahyayaucha H, Gallego M, Casis O and Bennouna M: Changes in erythrocyte morphology induced by imipramine and chlorpromazine. J Physiol Biochem 62: 199-205, 2006.
5. Misztal-Dethloff B, Stepien H and Komorowski J: Effect of diazepam and chlorpromazine on proliferative activity and vascular endothelial growth factor (VEGF) secretion from cultured endothelial HECa10 cells in vitro. Pharmacol Rep 57: 670-674, 2005.
6. Viskin S, Berger M, Ish-Shalom M, et al: Intravenous chlorpromazine for the emergency treatment of uncontrolled symptomatic hypertension in the pre-hospital setting: data from 500 consecutive cases. Isr Med Assoc J 7: 812-815, 2005. (Pubitemid 43009244)
7. Ximenes VF, Rodrigues AP, Cabello C, de Menezes ML and Fernandes JR: The co-catalytic effect of chlorpromazine on peroxidase-mediated oxidation of melatonin: enhanced production of N1-acetyl-N2-formyl-5-methoxykynuramine. J Pineal Res 44: 115-120, 2008. (Pubitemid 351252912)
8. Shin SY, Kim CG, Kim SH, Kim YS, Lim Y and Lee YH: Chlorpromazine activates p21Waf1/Cip1 gene transcription via early growth response-1 (Egr-1) in C6 glioma cells. Exp Mol Med 42: 395-405, 2010.
9. Kulkarni SK, Bishnoi M and Chopra K: In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration. Indian J Exp Biol 47: 91-97, 2009.
10. Nsimba SE: Effects of daily chlorpromazine administration on behavioural and physiological parameters in the rat. Indian J Physiol Pharmacol 53: 209-218, 2009.
11. Liu W, Li W, Yin W, et al: Preparation of a monoclonal antibody and development of an indirect competitive ELISA for the detection of chlorpromazine residue in chicken and swine liver. J Sci Food Agric 90: 1789-1795, 2010.
12. Sakai S, Ikematsu K, Matsuo A, Tsai CT and Nakasono I: Expression of C-fos, Fos-B, Fosl-1, Fosl-2, Dusp-1 and C-jun in the mouse heart after single and repeated chlorpromazine administrations. Leg Med (Tokyo) 12: 284-288, 2010.
13. Li T, Zhou Q, Zhang N and Luo Y: Toxic effects of chlorpromazine on Carassius auratus and its oxidative stress. J Environ Sci Health B 43: 638-643, 2008.
14. Xu B, Xu ZF, Deng Y and Yang JH: Protective effects of chlorpromazine and verapamil against cadmium-induced kidney damage in vivo. Exp Toxicol Pathol 62: 27-34, 2010.
15. Helin HO, Lundin ME, Laakso M, Lundin J, Helin HJ and Isola J: Virtual microscopy in prostate histopathology: simultaneous viewing of biopsies stained sequentially with hematoxylin and eosin, and alpha-methylacyl-coenzyme A racemase/p63 immunohistochemistry. J Urol 175: 495-499, 2006. (Pubitemid 43067336)
16. De Rossi A, Rocha LB and Rossi MA: Application of fluorescence microscopy on hematoxylin and eosin-stained sections of healthy and diseased teeth and supporting structures. J Oral Pathol Med 36: 377-381, 2007. (Pubitemid 46889877)
17. Smith PS, Parkinson IH and Leong AS: Principles of ploidy analysis by static cytometry. Clin Mol Pathol 49: M104-M111, 1996. (Pubitemid 26143354)
18. Dong J, Yin H, Liu W, Wang P, Jiang Y and Chen J: Congenital iodine deficiency and hypothyroidism impair LTP and decrease C-fos and C-jun expression in rat hippocampus. Neurotoxicology 26: 417-426, 2005. (Pubitemid 40780018)
19. van Kuijk AW, Gerlag DM, Vos K, et al: A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis 68: 1303-1309, 2009.
20. Delva E and Kowalczyk AP: Regulation of cadherin trafficking. Traffic 10: 259-267, 2009.
21. Hertel N and Redies C: Absence of layer-specific cadherin expression profiles in the neocortex of the reeler mutant mouse. Cereb Cortex 21: 1105-1117, 2011.
22. Lewis-Tuffin LJ, Rodriguez F, Giannini C, et al: Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One 5: e13665, 2010.
23. Martinez-Rico C, Pincet F, Thiery JP and Dufour S: Integrins stimulate E-cadherin-mediated intercellular adhesion by regulating Src-kinase activation and actomyosin contractility. J Cell Sci 123: 712-722, 2010.
24. Sivasankar S, Zhang Y, Nelson WJ and Chu S: Characterizing the initial encounter complex in cadherin adhesion. Structure 17: 1075-1081, 2009.
25. Baranwal S and Alahari SK: Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun 384: 6-11, 2009.
26. Yang I, Chang O, Lu Q and Kim K: Delta-catenin affects the localization and stability of p120-catenin by competitively interacting with E-cadherin. Mol Cells 29: 233-237, 2010.
27. Lapyckyj L, Castillo LF, Matos ML, Gabrielli NM, Luthy IA and Vazquez-Levin MH: Expression analysis of epithelial cadherin and related proteins in IBH-6 and IBH-4 human breast cancer cell lines. J Cell Physiol 222: 596-605, 2010.
28. Pontes J Jr, Srougi M, Borra PM, Dall' Oglio MF, Ribeiro-Filho LA and Leite KR: E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol 18: 179-184, 2010.
29. Karpowicz P, Willaime-Morawek S, Balenci L, DeVeale B, Inoue T and van der Kooy D: E-Cadherin regulates neural stem cell self-renewal. J Neurosci 29: 3885-3896, 2009.
30. Espada J, Galaz S, Sanz-Rodriguez F, et al: Oncogenic H-Ras and PI3K signaling can inhibit E-cadherin-dependent apoptosis and promote cell survival after photodynamic therapy in mouse keratinocytes. J Cell Physiol 219: 84-93, 2009.
31. Ben Nasr H, Hamrita B, Batbout M, et al: A single nucleotide polymorphism in the E-cadherin gene promoter -160 C/A is associated with risk of nasopharyngeal cancer. Clin Chim Acta 411: 1253-1257, 2010.
32. Ayollo DV, Zhitnyak IY, Vasiliev JM and Gloushankova NA: Rearrangements of the actin cytoskeleton and E-cadherin-based adherens junctions caused by neoplasic transformation change cell-cell interactions. PLoS One 4: e8027, 2009.
33. Canel M, Serrels A, Anderson KI, Frame MC and Brunton VG: Use of photoactivation and photobleaching to monitor the dynamic regulation of E-cadherin at the plasma membrane. Cell Adh Migr 4: 491-501, 2010.
34. Tsai TH, Chen SF, Huang TY, et al: Impaired Cd14 and Cd36 expression, bacterial clearance, and Toll-like receptor 4-Myd88 signaling in caveolin-1-deleted macrophages and mice. Shock 35: 92-99, 2011.
35. Corn PG and Thompson TC: Identification of a novel prostate cancer biomarker, caveolin-1: implications and potential clinical benefit. Cancer Manag Res 2: 111-122, 2010.
36. Zhu H, Yue J, Pan Z, et al: Involvement of Caveolin-1 in repair of DNA damage through both homologous recombination and non-homologous end joining. PLoS One 5: e12055, 2010.
37. Mastrodonato M, Calamita G, Rossi R, et al: Altered distribution of caveolin-1 in early liver steatosis. Eur J Clin Invest 41: 642-651, 2011.
38. Jasmin JF, Rengo G, Lymperopoulos A, et al: Caveolin-1 deficiency exacerbates cardiac dysfunction and reduces survival in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 300: H1274-H1281, 2011.
39. Sadegh MK, Ekman M, Rippe C, et al: Biomechanical properties and innervation of the female caveolin-1-deficient detrusor. Br J Pharmacol 162: 1156-1170, 2011.
40. Gildea JJ, Kemp BA, Howell NL, Van Sciver RE, Carey RM and Felder RA: Inhibition of renal caveolin-1 reduces natriuresis and produces hypertension in sodium-loaded rats. Am J Physiol Renal Physiol 300: F914-F920, 2011.
41. Gao C, Li R, Huan J and Li W: Caveolin-1 siRNA increases the pulmonary microvascular and alveolar epithelial permeability in rats. J Trauma 70: 210-219, 2011.
42. Ding H, Zhou FQ, Cai HR, Zhou YH and Meng FQ: [Expression of caveolin-1 and extracellular matrix induced by transforming growth factor beta1 in human fetal lung fibroblasts]. Zhonghua Jie He He Hu Xi Za Zhi 33: 280-283, 2010.
43. Borza CM, Chen X, Mathew S, et al: Integrin {alpha}1{beta}1 promotes caveolin-1 dephosphorylation by activating T cell protein-tyrosine phosphatase. J Biol Chem 285: 40114-40124, 2010.
44. Beauchesne E, Desjardins P, Butterworth RF and Hazell AS: Up-regulation of caveolin-1 and blood-brain barrier breakdown are attenuated by N-acetylcysteine in thiamine deficiency. Neurochem Int 57: 830-837, 2010.
45. Trimmer C, Sotgia F, Whitaker-Menezes D, et al: Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biol Ther 11: 383-394, 2011.
46. Rungtabnapa P, Nimmannit U, Halim H, Rojanasakul Y and Chanvorachote P: Hydrogen peroxide inhibits non-small cell lung cancer cell anoikis through the inhibition of caveolin-1 degradation. Am J Physiol Cell Physiol 300: C235-C245, 2011.
47. Luanpitpong S, Talbott SJ, Rojanasakul Y, et al: Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1. J Biol Chem 285: 38832-38840, 2010.
48. 2 and shear stress. Free Radic Biol Med 49: 159-170, 2010.
49. Yang SF, Yang JY, Huang CH, et al: Increased caveolin-1 expression associated with prolonged overall survival rate in hepatocellular carcinoma. Pathology 42: 438-445, 2010.
50. Pojoga LH, Adamova Z, Kumar A, et al: Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice. Am J Physiol Heart Circ Physiol 298: H1776-H1788, 2010.
51. Kapoor A, Hsu WM, Wang BJ, et al: Caveolin-1 regulates γ-secretase-mediated AßPP processing by modulating spatial distribution of γ-secretase in membrane. J Alzheimers Dis 22: 423-442, 2010.
52. Rhim JH, Kim JH, Yeo EJ, Kim JC and Park SC: Caveolin-1 as a novel indicator of wound-healing capacity in aged human corneal epithelium. Mol Med 16: 527-534, 2010.
53. Feher A, Rutkai I, Beleznai T, et al: Caveolin-1 limits the contribution of BK(Ca) channel to EDHF-mediated arteriolar dilation: implications in diet-induced obesity. Cardiovasc Res 87: 732-739, 2010.
54. Buitrago C and Boland R: Caveolae and caveolin-1 are implicated in 1alpha, 25(OH)2-vitamin D3-dependent modulation of Src, MAPK cascades and VDR localization in skeletal muscle cells. J Steroid Biochem Mol Biol 121: 169-175, 2010.
55. Mirza MK, Yuan J, Gao XP, et al: Caveolin-1 deficiency dampens Toll-like receptor 4 signaling through eNOS activation. Am J Pathol 176: 2344-2351, 2010.